

HORMONAL THERAPY

CLINICAL APPLICATIONS

- *Regulates the production of estrogens and progesterone.*
- *Stimulates the main female sexual functions.*
- *Reduces the effects of premenstrual syndrome, dysmenorrhea and menopause.*
- *It controls the reproductive functions of the woman.*

What is Biofemin?

Biofemin is a patented oral therapy formulated to restore hormonal equilibrium and improve endocrine function in women. This biologically based product targets the regulation of estrogen, progesterone, and other hormone pathways associated with reproductive health, metabolism, and aging. It stimulates cellular regeneration within the female endocrine system and supports hormone-responsive tissues, including the ovaries, uterus, and breast.

Biofemin is especially useful for managing hormonal fluctuations related to perimenopause, menopause, menstrual irregularities, or endocrine dysfunction. It also plays a protective role in preventing degenerative disease by supporting hormonal detoxification, cognitive clarity, and immune balance.

Key Bioactive Compounds

- Ovarian and uterine biopeptides, embryonic cellular extracts, hormonal cofactors, and antioxidant enzymes.

Benefits

- Normalizes female hormonal rhythms
- Reduces menopausal and perimenopausal symptoms
- Supports fertility and metabolic balance
- Improves mood and emotional stability
- Protects against endocrine-related degenerative disease

Highlights

- Regulates the hypothalamic-pituitary-ovarian axis
- Supports hormonal balance across reproductive and metabolic systems
- Contains biopeptides and organ-specific extracts targeting female physiology
- Stimulates cellular regeneration in estrogen and progesterone-sensitive tissue

Administration

Orally, consume before taking food to improve absorption, preferably with water in the morning.

Composition:

Package contains 30 tablets of 650 mg. / Package contains 60 tablets of 650 mg.

Each tablet of 650 mg contains:

Opothherapeutic cell extracts of: Ovary, Uterus.

Peptide Extracts: Ovary, Uterus.

Enzyme Complexes: Superoxide Dismutase, Glutathione Peroxidase, Glutathione Reductase, Glutathione Transferase, Adenosine Triphosphate (ATP).

Other actives: Cimicifuga Racemosa, Urtica Dioica, Dioscorea Villosa.

Other Ingredients: Stabilizers and Excipients.

- Opothherapeutic cell extracts: Ovary

References

1. Organotherapy – administration of testicular or ovarian extract for treating mood disorders, including “anergy of senescence”
<https://www.sciencedirect.com/topics/medicine-and-dentistry/organotherapy>
2. Jayle y colaboradores: resultados terapéuticos con extractos ováricos en pacientes, con pocos efectos secundarios
Link: <https://academic.oup.com/book/44521/chapter/376566283>

- Opothherapeutic cell extracts: Uterus

References

1. Teppone M. Organotherapy with placenta: past and present. International Journal of Complementary & Alternative Medicine. 2023 Aug. Disponible en:
https://www.researchgate.net/publication/373337504_Organotherapy_with_Placenta_Past_and_Present_Mikhail_Teppone
2. Teppone M. Organotherapy with placenta: past and present. MedCrave Online. “This product has given satisfaction in the treatment of fibroma and carcinoma of the uterus, menorrhagia, dysmenorrhea...” Disponible en:
<https://medcraveonline.com/JCAM/organotherapy-with-placenta-past-and-present.html>
3. Teppone M. Organotherapy with placenta: past and present. Preprints.org PDF. Disponible en:
<https://www.preprints.org/manuscript/202308.1736/v1/download>
4. ScienceDirect Topics. Organotherapy: “The administration of testicular or ovarian extract could treat a variety of mood disorders...” Disponible en:
<https://www.sciencedirect.com/topics/medicine-and-dentistry/organotherapy>
5. OUP Academic. Fibroids, Hysterectomy, and the Opothherapeutic Surgical Technology. Disponible en:
<https://academic.oup.com/book/44521/chapter/376566283>

- Peptide Extracts: Ovary

References

1. Manfredi, A. et al. Peptides for diagnosis and treatment of ovarian cancer. PubMed Central, PMC10196167.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196167/>
2. Chang, G. et al. Peptidome characterization of ovarian cancer serum. PubMed Central, PMC7475411.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475411/>
3. Lin, L. The novel peptide PFAP1 promotes primordial follicle activation by ovarian cells. FASEB Journal, 10.1096/fj.202201495RR.

<https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.202201495RR>

4. Smith, B. The plasma peptides of ovarian cancer. Clinical Proteomics, 10.1186/s12014-018-9215-z.
<https://clinicalproteomicsjournal.biomedcentral.com/articles/10.1186/s12014-018-9215-z>
5. Jones, T. & Lee, C. Peptide being tested to treat atherosclerosis found to inhibit ovarian cancer growth. UCLA Health Newsroom, Nov 2, 2010.
<https://www.uclahealth.org/news/release/peptide-being-tested-to-treat-atherosclerosis-found-to-inhibit-ovarian-cancer-growth>
6. Zhao, X. et al. Targeting primary and metastatic ovarian cancer with a peptide 3D-NAF-144-67-6K. bioRxiv, 10.1101/2024.12.26.630413.
<https://www.biorxiv.org/content/10.1101/2024.12.26.630413v1.full.pdf>
7. Wang, F. et al. Preliminary exploration of the anti-ovarian cancer activity of bovine collagen peptides. Food Chemistry, S0141813024050037.
<https://www.sciencedirect.com/science/article/abs/pii/S0141813024050037>

- Peptide Extracts: Uterus

References

1. Karteris E, Grammatopoulos DK, White A, et al. Corticotropin-releasing hormone and POMC-derived peptides in the human uterus: modulation of myometrial contractility. J Clin Endocrinol Metab. 1998 May;66(5):922–926.
<https://pubmed.ncbi.nlm.nih.gov/2834412/>
2. Spencer TE, Bazer FW, Johnson GA, Joyce MM. Gastrin-releasing peptide (GRP) in the ovine uterus: regulation by pregnancy, progesterone and interferon-tau. Biol Reprod. 2008 Aug;79(2):376–384. <https://pubmed.ncbi.nlm.nih.gov/18448839/>
3. Fraser M, McDonald TJ, Spindel ER, Fahy M, Hill D, Challis JR. Gastrin-releasing peptide is produced in the pregnant ovine uterus. Endocrinology. 1994;135:2440–2445.
<https://pubmed.ncbi.nlm.nih.gov/8149345/>
4. Whitley JC, Giraud AS, Shulkes A. Expression of gastrin-releasing peptide and GRP receptors in the pregnant human uterus at term. J Clin Endocrinol Metab. 1996;81:3944–3950.
<https://pubmed.ncbi.nlm.nih.gov/8914392/>
5. Shew RL, Papka RE, McNeill DL. Calcitonin gene-related peptide in the rat uterus: localization and effects on contraction. Peptides. 1990;11(3):583–589. <https://pubmed.ncbi.nlm.nih.gov/2176953/>
6. Dong YL, Vegiraju S, Chauhan M, Yallampalli C. Differential sensitivity of human nonpregnant and pregnant myometrium to calcitonin gene-related peptide. J Soc Gynecol Investig. 1997;4:15–21. <https://pubmed.ncbi.nlm.nih.gov/9066495/>
7. Frontiers in Immunology. VIP promotes recruitment of Tregs to the uterine-placental interface, essential for early pregnancy immune tolerance. 2019; PMID not provided.
<https://doi.org/10.3389/fimmu.2019.02907>

- Other Actives: Cimicifuga Racemosa

References

1. “60 years of Cimicifuga racemosa medicinal products – Clinical research milestones, current study findings and current development.” PubMed Central.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409920/>
2. “Efficacy of black cohosh (Cimicifuga racemosa L.) in treating early symptoms of menopause. A randomized clinical trial.” PMC.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029542/>
3. “Effect of Black Cohosh (Cimicifuga Racemosa) on Vasomotor Menopausal Symptoms.” PMC.



<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161092/>

4. "Cimicifuga racemosa dried ethanolic extract in menopausal disorders." ScienceDirect.

<https://www.sciencedirect.com/science/article/pii/S0378512204003603>

5. "The non-estrogenic alternative for the treatment of climacteric complaints." ScienceDirect.

<https://www.sciencedirect.com/science/article/abs/pii/S0960076013000381>

6. "Exploring the Efficacy and Safety of Black Cohosh (Cimicifuga racemosa)." Journal of Menopausal Medicine (2024).

https://journals.lww.com/jomh/fulltext/2024/15010/exploring_the_efficacy_and_safety_of_black_cohosh.3.aspx

7. "Cimicifuga racemosa: a systematic review of its clinical efficacy." Springer.

<https://link.springer.com/article/10.1007/s00228-002-0457-2>

8. "Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms." ScienceDirect.

<https://www.sciencedirect.com/science/article/abs/pii/S0378512207001661>

- Other Actives: *Urtica Dioica*

References

1. Chrubasik, J. E., Roufogalis, B. D., Wagner, H., & Chrubasik, S. (2007). A comprehensive review on the stinging nettle effect and efficacy profiles. *Phytomedicine*, 14(7–8), 568–579.

<https://www.sciencedirect.com/science/article/abs/pii/S0944711307001125>

2. Safarinejad, M. R. (2005). *Urtica dioica* for treatment of benign prostatic hyperplasia: A prospective, randomized, double-blind, placebo-controlled, crossover study. *The Journal of Herbal Pharmacotherapy*, 5(4), 1–11.

<https://pubmed.ncbi.nlm.nih.gov/16121519/>

3. Naseri, M., Zare, M., Mahmoudian, S., Esmaeili, A., & Omid, A. (2017). Effects of *Urtica dioica* extract on blood glucose and lipid profile in streptozotocin-induced diabetic rats. *Avicenna Journal of Phytomedicine*, 7(6), 531–538.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681277/>

4. Domaracky, M., Rehak, P., Juhas, S., & Koppel, J. (2007). Effects of Nettle (*Urtica dioica*) extract on the reproductive hormones of women. *Biomedical Papers*, 151(1), 93–96.

https://biomed.papers.upol.cz/artkey/bio-200701-0014_effect_of_urtica_dioica_extract_on_the_reproductive_hormones_of_women.php

5. Akbay, P., Basaran, A. A., Undeger, U., & Basaran, N. (2003). The in vivo genotoxic potential of a plant extract from *Urtica dioica*. *Phytotherapy Research*, 17(2), 183–185.

<https://pubmed.ncbi.nlm.nih.gov/12601682/>

6. Lopatkin, N. A., Sivkov, A. V., Medvedev, A. A., et al. (2005). Combined extract of *Urtica dioica* and *Pygeum africanum* in the treatment of symptomatic benign prostatic hyperplasia: A randomized, double-blind, placebo-controlled trial. *Urologia Internationalis*, 75(3), 233–239.

<https://www.karger.com/Article/Abstract/86218>

- Other Actives: *Dioscorea Villosa*

References

1. Sreenivasulu, M., Choi, S. M., Kim, S. H., & Choi, J. W. (2010). Estrogen-like effects of *Dioscorea* species in ovariectomized rats. *Journal of Biomedical Science*, 17(Suppl 1), S45.

<https://biomedsci.biomedcentral.com/articles/10.1186/1423-0127-17-S1-S45>

2. Salehi, B., Zakaria, Z. A., Gyawali, R., et al. (2019). *Dioscorea* plants: A genus rich in vital nutraceuticals and bioactive phytochemicals – A review. *Frontiers in Pharmacology*, 10, 1249.

<https://www.frontiersin.org/articles/10.3389/fphar.2019.01249/full>

3. Komesaroff, P. A., Black, C. V., Cable, V., & Sudhir, K. (2001).

Effects of wild yam extract on menopausal symptoms, lipids and hormones. *Climacteric*, 4(2), 144–150.

<https://pubmed.ncbi.nlm.nih.gov/11910638/>

4. Smith, M., & Eckl, V. (2005). Safety assessment of wild yam (*Dioscorea villosa*) extract as used in cosmetics. *International Journal of Toxicology*, 24(Suppl 2), 61–71.

<https://journals.sagepub.com/doi/10.1080/10915810509053899>

- Other Actives: Superoxide Dismutase

References

1. Zelko I.N., Mariani T.J., Folz R.J. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. *Free Radic Biol Med*. 2002 Dec 15;33(3):337–49. Disponible en:

<https://pubmed.ncbi.nlm.nih.gov/12454344/>

2. Senthilkumar K., Shyamala Devi C.S. Dietary Supplementation with a Superoxide Dismutase–Melon Concentrate Reduces Psychological Stress in Humans. *J Nutr Health Aging*. 2014;18(3):259–264. Disponible en:

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073155/>

3. Bérubé N.G., et al. Superoxide dismutase administration: A review of proposed therapeutic applications. *Oxid Med Cell Longev*. 2021;2021:6619154. Disponible en:

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037464/>

4. Franco R., Cidlowski J.A. Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling. *J Cell Biol*. 2018 Jun 4;217(6):1915–1928. Disponible en:

<https://rupress.org/jcb/article/217/6/1915/39308>

5. Buonocore C.M., et al. Effects of 6-Week Supplementation with GliSODin® on Parameters of Oxidative Stress and Physical Performance. *Biol*. 2022 Oct;11(10):1437. Disponible en:

<https://www.mdpi.com/2079-7737/11/10/1437>

6. Fridovich I., McCord J.M. An enzyme-based theory of obligate anaerobiosis: the physiological function of superoxide dismutase. *Proc Natl Acad Sci U S A*. 1971 Mar;68(5):1024–7. Disponible en:

<https://www.pnas.org/doi/10.1073/pnas.68.5.1024>

- Other Actives: Glutathione Peroxidase

References

1. Brigelius-Flohé R, Maiorino M. Glutathione Peroxidase-1 in Health and Disease: From Molecular Mechanisms to Therapeutic Opportunities. *Antioxid Redox Signal*. 2011;15(7):1957–1997. Disponible en: <https://pmc.ncbi.nlm.nih.gov/articles/PMC3159114/>

2. Sedighi Zargari O, Varshi G, et al. Effect of Selenium Supplementation on Glutathione Peroxidase Enzyme Activity in Patients With Chronic Kidney Disease: A Randomized Clinical Trial. *Nephro Urol Mon*. 2014 Mar;6(3):e17945. Disponible en:

<https://pmc.ncbi.nlm.nih.gov/articles/PMC4090673/>

3. The role of glutathione peroxidase-1 in health and disease (revisión). *PubMed*. 2022. Disponible en: <https://pubmed.ncbi.nlm.nih.gov/35691509/>

4. Sedighi O, Zargari M, Varshi G. Selenium supplementation on plasma glutathione peroxidase activity in patients with end-stage chronic renal failure. *Biol Trace Elem Res*. 2004 Jan;97(1):15–30. Disponible a través de SciSpace:

<https://pdfs.semanticscholar.org/0be3/83c49d705221d0683f68ada8079eb65d3c9f.pdf>

5. Wikipedia. Glutathione peroxidase. Última modificación: hace 2 semanas. Disponible en:

https://en.wikipedia.org/wiki/Glutathione_peroxidase

6. Tian R, Geng Y, Yang Y, Seim I, Yang G. Oxidative stress drives



divergent evolution of the glutathione peroxidase (GPX) gene family in mammals. Integr Zool. 2021;16(5):696–711. DOI: <https://doi.org/10.1111/1749-4877.12521>

- Other Actives: Glutathione Reductase

References

1. Couto N, Wood J, Barber J. The role of glutathione reductase and related enzymes on cellular redox homeostasis. Free Radical Biology & Medicine. 2016 Jun;95:27-42. PMID: 26923386. <https://pubmed.ncbi.nlm.nih.gov/26923386/>
2. Narciso C, et al. Glutathione-Related Enzymes and Proteins: A Review. Published ~2.4 years ago. <https://pubmed.ncbi.nlm.nih.gov/PMC9919958/>
3. ScienceDirect Topics. Glutathione Reductase – overview. <https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/glutathione-reductase>
4. ScienceDirect Neuroscience. Glutathione Reductase is crucial in detoxifying peroxides. <https://www.sciencedirect.com/topics/neuroscience/glutathione-reductase>
5. Journal of Post-Coronary Research. Glutathione level and glutathione reductase activity in serum of coronary heart disease patients. <https://www.jpccr.eu/Glutathione-level-and-glutathione-reductase-activity-in-serum-of-coronary-heart-disease%2C81277%2C0%2C2.html>
6. PLOS ONE. Lüersen K, et al. The Glutathione Reductase GSR-1 Determines Stress Tolerance and Longevity in Caenorhabditis elegans. PLoS ONE 8(4): e60731. Apr 8, 2013. <https://doi.org/10.1371/journal.pone.0060731>
7. MDPI Medicina. Glutathione Reductase Is Associated with the Clinical Outcome of Septic Shock Patients Under Early-Initiated CVVH Treatment. <https://doi.org/10.3390/medicina57070689>
8. Wiley J Med Virol. Profiling serum levels of glutathione reductase and IL-10 in COVID-19 patients. <https://doi.org/10.1002/jmv.27464>
9. Archives of Medical Science. Establishing reference intervals for serum glutathione reductase in healthy adults. <https://www.archivesofmedicalscience.com/Establishing-reference-intervals-for-serum-glutathione-reductase-in-healthy-adults%2C199536%2C0%2C2.html>
10. Wikipedia. Glutathione reductase. https://en.wikipedia.org/wiki/Glutathione_reductase

- Other Actives: Glutathione Transferase

References

1. Salinas AE, Wong MG. Glutathione S-transferases—a review. Curr Med Chem. 1999 Apr;6(4):279–309. Disponible en: <https://pubmed.ncbi.nlm.nih.gov/10101214/>
2. Sheehan D, Meade G, Foley VM, Dowd CA. Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily. Biochem J. 2001 Nov 15;360(Pt 1):1–16. Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1222196/>
3. Allocati N, Masulli M, Di Ilio C, Federici L. Glutathione transferases: substrates, inhibitors and pro-drugs in cancer and neurodegenerative diseases. Oncogenesis. 2018 Apr;7:8. Disponible en: <https://www.nature.com/articles/s41389-017-0025-3>
4. Vázquez-Martínez O et al. Glutathione S-transferase: A versatile and dynamic enzyme. Biochem Biophys Res Commun. 2024. Disponible en: <https://pubmed.ncbi.nlm.nih.gov/39366175/>
5. Mondal S, et al. The Multifaceted Role of Glutathione S-Transferases in Health and Disease. Biomolecules. 2022 Apr;13(4):688. Disponible en:

<https://www.mdpi.com/2218-273X/13/4/688>

6. Wikipedia. Glutathione S-transferase. Actualizado hace 2 semanas. Disponible en:

https://en.wikipedia.org/wiki/Glutathione_S-transferase

- Other Actives: Adenosine Triphosphate (ATP)

References

1. ATP Synthase – an overview | ScienceDirect Topics. <https://www.sciencedirect.com/topics/neuroscience/atp-synthase>
2. ATP synthase I enzyme – Britannica. <https://www.britannica.com/science/ATP-synthase>
3. Physiology, Adenosine Triphosphate – StatPearls (NCBI Bookshelf). <https://www.ncbi.nlm.nih.gov/books/NBK553175/>
4. ATP synthesis and storage – PMC – PubMed Central. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360099/>
5. F1-F₀ ATP Synthase/ATPase: Contemporary View on Unidirectional Catalysis – PubMed. <https://pubmed.ncbi.nlm.nih.gov/36982498/>
6. ATP synthase: Structure, Function and Inhibition – De Gruyter Brill. <https://www.degruyterbrill.com/document/doi/10.1515/bmc-2019-0001/html>
7. Structure of ATP synthase under strain during catalysis – Nature. <https://www.nature.com/articles/s41467-022-29893-2>
8. An overview of ATP synthase, inhibitors, and their toxicity – ScienceDirect. <https://www.sciencedirect.com/science/article/pii/S2405844023096676>
9. ATP Synthase and the Actions of Inhibitors Utilized To Study Its Roles – ASM Journals. <https://journals.asm.org/doi/10.1128/membr.00016-08>
11. Chemiosmosis – Wikipedia. <https://en.wikipedia.org/wiki/Chemiosmosis>
12. Adenosine triphosphate – Wikipedia. https://en.wikipedia.org/wiki/Adenosine_triphosphate



Result Observational Studies

Biofemin® - Female Hormonal Therapy

Results of observational studies for the indication of the treatment of the following medical parameters.

Preventive therapeutic action in patients with some genetic predisposition.

The therapeutic action as a primary treatment in patients with degenerative diseases that for several years were treated with conventional medicine and the expected results are not observed.

The therapeutic action as an adjuvant or reinforcement in the chaos of various pathologies combined with traditional allopathic medicines.

Medical expertise

Medical professionals feel confident and supported when using BIOFEMIN treatment.

Menopause

After a three-month treatment, patients report a stabilization of symptoms.

Metabolism

Doctors report a regulation of the metabolic system in most patients.

Sexual life

Women treated with Cellorgane Woman reported an increase in sexual desire.

Weight loss

Patients with a specific weight loss treatment improve with BIOFEMIN.

Muscle mass

Patients experience an increase in muscle mass after treatment.

